Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer
Intravesical instillation of Mycobacterium bovis bacillus Calmette-Guérin (BCG) has been used for treating bladder cancer for 3 decades. However, BCG therapy is ineffective in approximately 30–40% of cases. Since evidence supports the T helper type 1 (Th1) response to be essential in BCG-induced tum...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2011-01-01
|
| Series: | Clinical and Developmental Immunology |
| Online Access: | http://dx.doi.org/10.1155/2011/728930 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832559382815047680 |
|---|---|
| author | Yi Luo Jonathan Henning Michael A. O'Donnell |
| author_facet | Yi Luo Jonathan Henning Michael A. O'Donnell |
| author_sort | Yi Luo |
| collection | DOAJ |
| description | Intravesical instillation of Mycobacterium bovis bacillus Calmette-Guérin (BCG) has been used for treating bladder cancer for 3 decades. However, BCG therapy is ineffective in approximately 30–40% of cases. Since evidence supports the T helper type 1 (Th1) response to be essential in BCG-induced tumor destruction, studies have focused on enhancing BCG induction of Th1 immune responses. Although BCG in combination with Th1 cytokines (e.g., interferon-α) has demonstrated improved efficacy, combination therapy requires multiple applications and a large quantity of cytokines. On the other hand, genetic manipulation of BCG to secrete Th1 cytokines continues to be pursued with considerable interest. To date, a number of recombinant BCG (rBCG) strains capable of secreting functional Th1 cytokines have been developed and demonstrated to be superior to BCG. This paper discusses current rBCG research, concerns, and future directions with an intention to inspire the development of this very promising immunotherapeutic modality for bladder cancer. |
| format | Article |
| id | doaj-art-e3491c6dee4a4ba1b55af7f89eee8ebd |
| institution | Kabale University |
| issn | 1740-2522 1740-2530 |
| language | English |
| publishDate | 2011-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Clinical and Developmental Immunology |
| spelling | doaj-art-e3491c6dee4a4ba1b55af7f89eee8ebd2025-02-03T01:30:12ZengWileyClinical and Developmental Immunology1740-25221740-25302011-01-01201110.1155/2011/728930728930Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder CancerYi Luo0Jonathan Henning1Michael A. O'Donnell2Department of Urology, University of Iowa, 375 Newton Road, 3202 MERF, Iowa City, IA 52242, USADepartment of Urology, University of Iowa, 375 Newton Road, 3202 MERF, Iowa City, IA 52242, USADepartment of Urology, University of Iowa, 375 Newton Road, 3202 MERF, Iowa City, IA 52242, USAIntravesical instillation of Mycobacterium bovis bacillus Calmette-Guérin (BCG) has been used for treating bladder cancer for 3 decades. However, BCG therapy is ineffective in approximately 30–40% of cases. Since evidence supports the T helper type 1 (Th1) response to be essential in BCG-induced tumor destruction, studies have focused on enhancing BCG induction of Th1 immune responses. Although BCG in combination with Th1 cytokines (e.g., interferon-α) has demonstrated improved efficacy, combination therapy requires multiple applications and a large quantity of cytokines. On the other hand, genetic manipulation of BCG to secrete Th1 cytokines continues to be pursued with considerable interest. To date, a number of recombinant BCG (rBCG) strains capable of secreting functional Th1 cytokines have been developed and demonstrated to be superior to BCG. This paper discusses current rBCG research, concerns, and future directions with an intention to inspire the development of this very promising immunotherapeutic modality for bladder cancer.http://dx.doi.org/10.1155/2011/728930 |
| spellingShingle | Yi Luo Jonathan Henning Michael A. O'Donnell Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer Clinical and Developmental Immunology |
| title | Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer |
| title_full | Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer |
| title_fullStr | Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer |
| title_full_unstemmed | Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer |
| title_short | Th1 Cytokine-Secreting Recombinant Mycobacterium bovis Bacillus Calmette-Guérin and Prospective Use in Immunotherapy of Bladder Cancer |
| title_sort | th1 cytokine secreting recombinant mycobacterium bovis bacillus calmette guerin and prospective use in immunotherapy of bladder cancer |
| url | http://dx.doi.org/10.1155/2011/728930 |
| work_keys_str_mv | AT yiluo th1cytokinesecretingrecombinantmycobacteriumbovisbacilluscalmetteguerinandprospectiveuseinimmunotherapyofbladdercancer AT jonathanhenning th1cytokinesecretingrecombinantmycobacteriumbovisbacilluscalmetteguerinandprospectiveuseinimmunotherapyofbladdercancer AT michaelaodonnell th1cytokinesecretingrecombinantmycobacteriumbovisbacilluscalmetteguerinandprospectiveuseinimmunotherapyofbladdercancer |